• NMPA certification secured, enabling launch in China
• Product positioned with leading hearing aid brand sold through top e-commerce channels
• Supports large-scale commercial rollout and visibility across dominant online healthcare platforms
• Strengthens Audeara's strategy to drive repeatable, high-margin licensing revenue through global partners

Audeara Limited (ASX: AUA) has announced that the hearing personalisation technology licensed to its long-term manufacturing partner Eastech has received National Medical Products Administration (NMPA) certification in China. This certification marks a key regulatory and commercialisation milestone as Audeara establishes its position within China's hearing aid market. Under the partnership, Audeara will supply its proprietary hearing personalisation technology, while Eastech leads product development, regulatory submissions and market readiness activities. Achieving NMPA certification confirms full regulatory compliance and positions the product for large-scale commercial rollout, including visibility across China's top-tier e-commerce marketplaces, which dominate national hearing aid purchasing behaviour. This milestone supports Audeara's global licensing and commercial expansion strategy, strengthens the company's position in the rapidly growing hearing health technology sector, and is expected to contribute to scalable, recurring licensing revenue as the product enters China's high-volume, market-leading e-commerce ecosystem.

The NMPA certification enables Eastech to commence production and activation planning ahead of the product launch in China. Under the licensing arrangement, Audeara will receive technology licensing revenue per unit sold as the commercial rollout occurs, contributing to the company's strategy to deliver repeatable, high-margin licensing revenue through global partners.